Multidisciplinary consensus-based statement on the current role of middle meningeal artery embolization (MMAE) in chronic SubDural hematoma (cSDH)
- PMID: 39717364
- PMCID: PMC11664065
- DOI: 10.1016/j.bas.2024.104143
Multidisciplinary consensus-based statement on the current role of middle meningeal artery embolization (MMAE) in chronic SubDural hematoma (cSDH)
Abstract
Introduction: Middle Meningeal Artery Embolization (MMAE) in patients with chronic SubDural Hematoma (cSDH) is a novel treatment approach, albeit the specific role of MMAE in the treatment of cSDH is not yet defined.
Research question: The aim of this work is to provide a consensus-based statement from a multidisciplinary panel on the current role of MMAE in patients with cSDH.
Materials and methods: A literature search was performed using the keywords MMAE and cSDH. Based on the available published data, the panel was asked if a consensus could be reached on the role of MMAE in both de novo as well as in recurrent cSDH.
Results: The panel reached a consensus on the current role of MMAE in both de novo- and recurrent cSDH, as well as in patients on antithrombotics and those with coagulopathy. MMAE should be considered in the following scenarios:1)As "stand-alone" treatment in de novo cSDH requiring intervention but where surgery is prevented due to either coagulopathy or in patients on antithrombotics in whom the risk of suspension is considered unacceptably high,2)as "stand-alone" treatment in recurrent cSDH requiring intervention but where surgery is prevented due to either coagulopathy or in those on antithrombotics in whom the risk of suspension is considered unacceptably high and3)as "adjunct to surgery" in all recurrent cSDH.
Discussion and conclusion: This statement is to be considered an expert consensus opinion of delegates representing key international medical societies of specialists involved in the care of cSDH patients.
Keywords: Anaesthesia; Chronic subdural hematoma; Endovascular; Geriatrics; Middle meningeal artery embolization; Neurosurgery.
© 2024 The Authors.
Conflict of interest statement
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jiri Bartek and all authors received editorial assistance and project facilitation support from Alison Crowe as declared in the manuscript reports administrative support was provided by Alison Crowe at corvus communications limited. Alessandra Biondi reports a relationship with Balt, Medtronic, Microvention, Penumbra and Stryker Neurovascular that includes: consulting or advisory and funding grants. Vincent Bonhomme reports a relationship with Medtronic, Edwards Medical, Orion Pharma, Grünenthal, and Elsevier as Deputy Editor-in-Chief of the Acta Anaesthesiologica Belgica that includes: consulting or advisory and funding grants. Lucio Castellan reports a relationship with Roche, Biogen, Stryker, VMLY Seagen, Seagen, Balt and H2O that includes: consulting or advisory, funding grants, and speaking and lecture fees. Corrado Iaccarino reports a relationship with Integra Life Science and Finceramica S.p.A. that includes: funding grants. Zsolt Kulcsar reports a relationship with Microvention, Stryker, Medtronic and Cerenovus that includes: consulting or advisory and funding grants. Markus Moelenbruch reports a relationship with Balt, Medtronic, Microvention, Stryker that includes: funding grants. Andreas Raabe reports a relationship with Zeiss that includes: consulting or advisory and funding grants. Carolina S Romero reports a relationship with Octapharma that includes: funding grants. David Shipway reports a relationship with Balt that includes: travel reimbursement. Carmine Sicignano reports a relationship with Balt that includes: speaking and lecture fees. Mario Muto reports a relationship with Stryker that includes: consulting or advisory. The Consensus Meeting was arranged and supported with the non-conditioning assistance of BALT. The EANS delegates (Jiri Bartek, Marco Cenzato and Andreas Rabbe) were not financially supported by BALT, the expenses of these were reimbursed by the EANS. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Similar articles
-
Chronic subdural hematoma recurrence due to contralateral neovascularization following middle meningeal artery embolization.Interv Neuroradiol. 2022 Dec;28(6):639-643. doi: 10.1177/15910199211065197. Epub 2021 Dec 13. Interv Neuroradiol. 2022. PMID: 34894830 Free PMC article.
-
Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: An Analysis of 35 Consecutive Patients.Cureus. 2023 Nov 20;15(11):e49098. doi: 10.7759/cureus.49098. eCollection 2023 Nov. Cureus. 2023. PMID: 38125256 Free PMC article.
-
Middle meningeal artery embolization for chronic subdural hematoma: a systematic review.Front Neurol. 2023 Oct 10;14:1259647. doi: 10.3389/fneur.2023.1259647. eCollection 2023. Front Neurol. 2023. PMID: 37881312 Free PMC article.
-
Initial experience using middle meningeal artery embolisation for patients with recurrent and high-recurrence-risk chronic subdural haematoma.J Clin Neurosci. 2024 Jul;125:126-131. doi: 10.1016/j.jocn.2024.05.022. Epub 2024 May 23. J Clin Neurosci. 2024. PMID: 38788605
-
Comparative outcomes of middle meningeal artery embolization with statins versus embolization alone in the treatment of chronic subdural hematoma: a systematic review and meta-analysis.Neurosurg Rev. 2023 Oct 3;46(1):262. doi: 10.1007/s10143-023-02165-3. Neurosurg Rev. 2023. PMID: 37783962
Cited by
-
Letter-to-the-editor to the study by Bartek J et al "Multidisciplinary consensus-based statement on the current role of Middle Meningeal Artery embolization (MMAE) in chronic SubDural Hematoma (cSDH)" - A letter from the international CSDH research group committee, iCORIC.Brain Spine. 2024 Dec 24;5:104169. doi: 10.1016/j.bas.2024.104169. eCollection 2025. Brain Spine. 2024. PMID: 39834717 Free PMC article. No abstract available.
-
Middle Meningeal Artery Embolization for the Treatment of Chronic Subdural Hematomas-a German Nationwide Multi-center Study On 718 Embolizations.Clin Neuroradiol. 2025 Aug 18. doi: 10.1007/s00062-025-01549-w. Online ahead of print. Clin Neuroradiol. 2025. PMID: 40824387
-
Adjunctive middle meningeal artery embolization for non-acute subdural hematoma: A GRADE-assessed meta-analysis and trial sequential analysis on randomized trials.Acta Neurochir (Wien). 2025 Jun 2;167(1):160. doi: 10.1007/s00701-025-06574-9. Acta Neurochir (Wien). 2025. PMID: 40455367 Free PMC article. Review.
-
Letter to the editor regarding the response to "Multidisciplinary consensus-based statement on the current role of Middle Meningeal Artery embolization (MMAE) in chronic SubDural Hematoma (cSDH)".Brain Spine. 2025 Jan 21;5:104186. doi: 10.1016/j.bas.2025.104186. eCollection 2025. Brain Spine. 2025. PMID: 39944726 Free PMC article. No abstract available.
-
Middle meningeal artery embolization in chronic subdural hematoma: a new tool in geriatric care.Eur Geriatr Med. 2025 Feb;16(1):1-3. doi: 10.1007/s41999-024-01121-8. Eur Geriatr Med. 2025. PMID: 39621205 No abstract available.
References
-
- Aguirre J.A., Etzensperger F., Brada M., et al. The beach chair position for shoulder surgery in intravenous general anesthesia and controlled hypotension: impact on cerebral oxygenation, cerebral blood flow and neurobehavioral outcome. J. Clin. Anesth. 2019;53:40–48. doi: 10.1016/j.jclinane.2018.09.035. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials